Obesity continues to increase in prevalence worldwide. Hypertension has long been associated with obesity, and weight loss continues to be a first-line therapy in the treatment of hypertension. Lifestyle modification and pharmacologic therapy, however, often meet with treatment failure. Bariatric surgery continues to be the most successful approach to sustained weight loss. This review focuses on the underlying physiologic mechanisms of obesity-hypertension, and the impact of bariatric surgery on the treatment of hypertension. Current available literature on the physiologic mechanisms of obesity-hypertension, and the major trials, meta-analyses and systematic reviews of the impact of bariatric surgery procedures on hypertension are reviewed. Evidence suggests significant improvement in obesity-hypertension in patients who undergo surgical weight-reduction procedures. Malabsorptive techniques such as the Roux-en-Y gastric bypass or surgical resection techniques such as laparoscopic sleeve gastrectomy appear to offer superior results in regards to hypertension control over restrictive techniques such as Gastric Banding. Though long-term control of hypertension following surgery remains a concern, available follow-up post-operative data of up to 10 years suggests a sustained, if lessened, effect on hypertension control over time.
Epidemiological studies continue to show an increasing prevalence of obesity worldwide, which has been strongly associated with the development of hypertension, along with other major metabolic and cardiovascular risk factors such as dyslipidemia and diabetes mellitus type II. [1] [2] [3] Though dietary modification and exercise continue to be the first-line approach to obesity and metabolic syndrome, sustained remission is rare with this treatment alone. [4] [5] [6] Pharmacologic options are increasing, however, variable response to medications for obesity and frequent side effects with this approach have limited overall success. 7 Weight loss has long been recognized as an effective treatment in the management of hypertension. 8, 9 The role of bariatric surgery in the long-term management of isolated hypertension, however, is less clear. Though a profound effect on hypertension is often seen early after surgery, concerns regarding safety to this approach as well as length of remission with bariatric surgery have persisted as longterm follow-up data is limited and suggestive of a lessened effect over time. 10, 11 Additionally, the extensive repertoire of effective antihypertensive medications has made bariatric surgery for isolated hypertension less attractive. 12 Nonetheless, surgical techniques continue to improve and simplify. As safety improves and data continues to emerge regarding the benefit of these techniques on hypertension management in conjunction with other metabolic parameters, bariatric surgery is an increasingly appealing treatment option for obesity. 13 A thorough understanding of the impact of bariatric surgery on hypertension, as well as other metabolic risk factors, is required of the clinician in order to guide patient treatment decisions in the management of obesity. This review will focus on the underlying mechanisms of hypertension in obesity, the physiologic effects of bariatric surgery in the treatment of hypertension, and an analysis of the available data on the various types of bariatric surgery and its longterm effect on hypertension management.
PHYSIOLOGY OF HYPERTENSION IN OBESITY
Classically, hypertension in obesity is attributed to excess plasma volume expansion and increased cardiac output due to excess body mass, with a concomitant decrease in natriuresis. 14, 15 Previously, our group demonstrated that both hypertensive and normotensive obese subjects have an increase in renal blood flow as well as total blood volume and cardiac output, but with a concomitant decrease in peripheral vascular resistance when compared with normal weight individuals. 16 This increase in cardiac output and vasodilation seen in obesity results in glomerular hyperfiltration, with subsequent increase in distal tubular sodium delivery. A variety of factors result in increased renin-angiotensin-aldosterone (RAAS) activation and sympathetic nervous system (SNS) activation, which ultimately results in increased sodium reabsorption, plasma volume expansion, and arterial hypertension (Figure 1 ). Though this mechanism of obesity-hypertension continues to evolve and develop greater complexity, with an increasing number of neurohormonal components implicated, the fundamental alteration of arterial pressure and sodium natriuresis continues to be the cornerstone of the development of hypertension. 15, [17] [18] [19] [20] The upregulation of the RAAS system in obesity, despite volume expansion which would typically downregulate this system, is perhaps the best-described mechanism for hypertension in this condition. Increased RAAS expression in obesity appears to occur through a variety of mechanisms. [21] [22] [23] [24] First, the adipocyte itself appears to be a major producer of angiotensinogen, the precursor in the RAAS system. Experimental research has shown in animal studies that as much as 30% of circulating angiotensinogen is derived from the adipocyte. 21 Furthermore, it appears inflamed adipocytes, as seen in visceral fat deposits, are particularly prone to angiotensinogen secretion; and research suggests this mechanism correlates in humans. [21] [22] [23] [24] Interestingly, recent research has shown that selective ablation of adipose-derived angiotensinogen in rodents made these animals immune to the development of hypertension, despite development of obesity. 25 These findings highlight the potentially prominent role of the adipocyte as a main driver of hypertension.
A second potential mechanism for hypertension in obesity is via increased RAAS expression from renal parenchymal compression due to extrinsic visceral fat deposits around the kidney, found in advanced stages of obesity. This compression may subsequently result in decreased effective renal blood flow and decreased renal tubular flow and sodium delivery, which is sensed by the macula densa, which in turn actives RAAS via the tubuloglomerular feedback mechanism. This finding could be comparable to, though more insidious than, the Page Kidney where sudden hypertension develops from extrarenal compression due to hemorrhage. Animal studies have been mixed in the degree to which this mechanism is responsible for hypertension in obesity, and the extent to which this exists in humans is unclear and is an area for future investigation. 14, [26] [27] [28] [29] A third mechanism contributing to and complicating RAAS dynamics in obesity is the discovery of extra-adrenal aldosterone production via visceral adipocytes. This aldosterone production does not appear to be influenced by traditional RAAS feedback dynamics and may help account for the observed increase in circulating aldosterone levels in some obese individuals. 30 As aldosterone increasingly is implicated in inflammation and fibrosis of multiple organs, including the heart, kidney, and vasculature, this may become an important target of future investigation.
In addition to RAAS upregulation, the SNS also appears to play a significant role in obesity-hypertension. Increased baseline sympathetic tone has been frequently observed in obesity, with multiple potential causes. [31] [32] [33] [34] Hyperinsulinemia and the metabolic syndrome are frequently encountered with obesity and it is recognized that insulin leads to direct stimulation of the SNS. 35 In addition to this mechanism, obstructive sleep apnea and sleep disordered breathing occur in a much greater percentage of obese patients than in the general population. Frequent nocturnal arousals in obstructive sleep apnea have been demonstrated to result in sympathetic bursts and increased sympathetic tone in this condition. 36, 37 A variety of other potential mechanisms may further be responsible for SNS activation in obesity and continue to be investigated.
More recently, the role of leptin in the development of obesity-hypertension has gained increased recognition. Though leptin secretion results in appetite suppression in the normal state, in obesity the body appears to develop leptin resistance. It is now well recognized that, contrary to many animal models of obesity in which hypoleptinemia results in polyphagia and obesity, the majority of human obese patients have elevated serum leptin levels. This in turn, appears to accelerate hypertension as Leptin acts as both a central SNS stimulant and may result directly in decreased natriuresis, though the precise mechanism of this is unclear. 19, [38] [39] [40] [41] Leptin infusion in animal subjects has been shown to acutely raise blood pressure. 42 An important but still poorly understood link in obesityhypertension is the role of Ghrelin. Ghrelin is predominately released by gastric cells in response to caloric restriction and has been shown to stimulate hunger, as well as growth hormone release. 43 Sleeve gastrectomy, where the fundus of the stomach (and thus the predominate source of circulating Ghrelin) is removed has been shown to result in reduction of plasma Ghrelin levels, whereas gastric banding has been shown to increase plasma Ghrelin levels; and this has been implicated as a potential mechanism for the greater effectiveness of surgical resection procedures compared to gastric banding. [44] [45] [46] Yet paradoxically, Ghrelin appears to have a predominately hypotensive effect in vivo via parasympathetic activation; and increased Ghrelin levels have shown potential to improve inflammation and downstream effects of hypertension such as cardiac hypertrophy. 47, 48 Likewise, hypertensive obese subjects have been shown to have lower circulating levels of ghrelin. 49 Nonetheless, if a reduction of gastric ghrelin production is proved to result in sustained weight loss and longer term improvement in hypertension and other metabolic parameters, this could open the door to nonsurgical, endovascular-based techniques to target the gastric fundus, potentially reducing overall risk and allowing for an even larger number of patients with obesity-related complications to be treated with a permanent weight-reduction procedure. [50] [51] [52] In addition to effects on ghrelin, Roux-en-Y gastric bypass (RYGB) and laparoscopic sleeve gastrectomy (LSG) procedures result in increased levels of glucogon-like peptide 1 (GLP-1) and peptide YY (PYY), which alter gut motility and likely aid in the weight loss seen in bariatric surgery. [53] [54] [55] The degree to which these gut hormones have a direct effect on hypertension, however, is less clear, though some evidence exists of a natriuretic effect of GLP-1. [56] [57] [58] Nonetheless, the influence and interplay of ghrelin, GLP-1, and PYY on obesity and the metabolic syndrome is clear, and new techniques to alter these hormones in the treatment of obesity represent a driving force in obesity research.
Beyond these mechanisms, it is apparent that the obese state is associated with an increasingly recognized number of other altered hormones, cytokines, and adipokines. The precise contribution of each of these individual circulating factors to the development of hypertension is still uncertain, but our understanding of this condition is rapidly evolving. A startling finding in bariatric surgery is that a profound antihypertensive effect occurs as early as 10 days postoperatively, long prior to any meaningful weight reduction. 59 This observation has caused many to conclude that gut hormones may play a greater, or at least a substantial, role in the process of obesity-hypertension than the traditionally recognized factors such as increased cardiac output and extrinsic renal compression. However, despite the immediate effects, a meta-analysis by Ricci et al., found that the reduction in hypertension risk continued to improve until about 20 months postsurgery, after which further hypertension reduction plateaued 60 ; which suggests that likely a combination of both immediate postsurgical hormonal changes, as well as delayed factors from weight reduction contributes to hypertension improvement following bariatric surgery.
DATA OUTCOMES OF BARIATRIC SURGERY AND HYPERTENSION
The data on hypertension improvement following bariatric surgery is somewhat mixed, with variable reports on control based on length of follow-up time as well as type of surgery performed. Nonetheless, the majority of evidence supports significant improvement in hypertension control with weight-reduction surgery (Table 1) . A large meta-analysis by Wilhelm, Young, and Kale-Pradhan, identified a total of 57 prospective or randomized trials, with surgical techniques including traditional RYGB, laparoscopic adjustable gastric banding (LAGB), vertical gastric banding (VGB), laparoscopic sleeve gastrectomy (LSG), duodenal switch, and biliopancreatic diversion. The majority of the studies included in this study had a relatively short follow-up period of less than 2 years. Nonetheless, the analysis was overall positive for treatment of hypertension, with 32/57 studies showing improvement in hypertension in 32,628 out of 51,241 patients (63.7%; odds ratio = 13.64; 95% confidence interval = 7.73, 22.68; P < 0.00001), and this persisted when analyzing only studies with greater than 1 year follow-up. 61 In this same analysis, when studies that reported resolution of hypertension were analyzed, resolution was found in 24,909 out of 49,844 patients (50%; odds ratio = 1.72; 95% confidence interval = 1.13, 2.62; P < 0.00001).
Likewise, Heneghan et al. showed a 68% reduction of obesity-hypertension in a separate meta-analysis, with a mean duration of follow-up of 34 months (range 3 months to 154 months). Importantly, 23% of studies included in this sample had a follow-up period of >48 months and remission of hypertension over this longer follow-up period was confirmed, attesting to long-term improvement in hypertension with bariatric procedures. 62 A second meta-analysis performed by this group 2 years later, with additional publications included, again corroborated the initial findings and demonstrated a 62.5% reduction in obesity-hypertension with follow-up ranging from 3 months to 14.7 years. 63 In regards to the type of surgery performed, the majority of studies indicate that bypass type surgeries and/or gastric resection (RYGB, biliopancreatic diversion, duodenal switch, SLG) lead to superior results when compared to purely restrictive surgeries such as gastric banding procedures. A large, earlier meta-analysis by Buchwald et al., demonstrated resolution of hypertension in 38.4% of patients undergoing laparoscopic gastric banding vs. 75.4% undergoing traditional RYGB, 72.5% in vertical banded gastroplasty, and 81.3% after biliopancreatic diversion/duodenal switch (BPD-DS). Further, overall improvement in hypertension with or without resolution was seen in 71.5%, 87.1%, 80.6%, and 91.8% of patients undergoing these same procedures, respectively. No data, however, was available from this metaanalysis regarding duration of treatment remission. 64 Similarly, a systematic review by Sarkosh et al., sought to determine the impact of sleeve gastrectomy, as it is a relatively newer bariatric procedure for weight loss, on the impact of hypertension improvement or remission. Their study found at 1 year, 58% of patients experience resolution of hypertension and 75% experienced improvement in hypertension after undergoing sleeve gastrectomy technique. This review demonstrated that sleeve gastrectomy resulted in improved results compared to gastric banding, and similar, if slightly less robust, results than traditional surgical gastric diversion techniques. 65 Further corroborating these findings, the Longitudinal Assessment of Bariatric Surgery (LABS) Consortium, was a multicenter, observational prospective cohort of patients undergoing bariatric surgery. The goal of the study was to assess the long-term safety and cardiovascular outcomes. Recently, Courcoulas et al., reported the 3-year results of this study. Of note, 1,738 patients in this study underwent RYGB, whereas an additional 610 underwent LAGB; while as smaller portion of 48 patients underwent sleeve gastrectomy, 39 patients underwent biliopancreatic diversion, and 48 patients underwent banded gastric bypass. Hypertension remission occurred in 38.2% of the RYGB patients, vs. 17.4% of the LAGB patients. It is worth noting that diabetes remission and dyslipidemia remission occurred approximately twice as often with RYGB vs. LAGB. 66 In terms of factors influencing hypertension remission, Flores et al., evaluated the rate of hypertension remission of 526 patients who underwent either sleeve gastrectomy or laparoscopic gastric bypass in a Spanish medical center. Of this population, approximately 50% had baseline hypertension. Twelve months following surgery, approximately 65% of the patients available for follow-up had remission of hypertension. Interestingly, only duration and severity of presurgical hypertension predicted a lack of remission postoperatively. Presurgical BMI, presence of type II DM, vitamin D status, baseline weight circumference, type of surgery, and excess weight loss did not correlate with remission. 67 As noted previously, duration of hypertension remission has been a cause for concern with bariatric surgery as a treatment for hypertension. In regards to long-term data, the best evidence regarding the effects of bariatric surgery on hypertension outcomes is from the Swedish Obese Subjects Study (SOS), in which 2 groups of each approximately 2,000 patients were followed prospectively after bariatric surgery vs. matched controls. Subjects underwent either gastric bypass or vertical banded gastroplasty or gastric banding. The initial data from this trial was underwhelming in regards to longterm hypertension control, with no difference in the overall incidence in hypertension between the control group and the treatment group at both 2 years and 10 years. Rates of recovery of hypertension were improved, however, at both time periods with 34% of the treatment group vs. 21% of control group showing recovery at 2 years (P < 0.001), and 19% of the treatment group vs. 11% of the control group showing recovery at 10 years (P < 0.02). Similar to other published data, the gastric bypass procedures appeared to have a much greater effect than gastric banding not only in regards to hypertension, but also in regards to diabetic remission, improvement in dyslipidemia, and to overall excess weight loss. 10 However, a re-analysis of the SOS data was published in 2012. The re-analysis was undertaken due to an increased number of 10-year follow-up data and to specifically examine the differences between the restrictive procedures (VBG/ LAGB) vs. the malabsorptive procedures (RYGB). In the repeat analysis, follow up for these procedures was 92% for both procedures at 2 years, and 68% in the gastric bypass vs. 74% in the gastric banding group at 10 years. The control group had a similar overall follow-up rate. Gastric bypass offered superior results both with regard to overall weight reduction, as well as to hypertension control. Average blood pressure was reduced by 12.1 mm Hg systolic and 7.3 mm Hg diastolic at 2-year follow-up, and by 5.1 mm Hg systolic and 5.6 mm Hg diastolic at 10-year follow-up in the group undergoing gastric bypass, a significant difference. The effect with gastric banding was roughly half that of gastric bypass. Significant improvement was seen in systolic and diastolic pressure reduction in the gastric banding group at 2 years when compared with controls, but this effect was negated at 10 years, and diastolic pressure actually favored controls when compared to this group at this timeframe. Interestingly, gastric bypass in this study also appeared to have a more pronounced increase in both urinary volume and sodium excretion compared to gastric banding at both 2 years and 10 years; suggesting a prominent natriuretic effect as an effect with the malabsorptive weight-reduction surgeries. 68 
CONCLUSION
Hypertension in obesity is a result of a complex relationship of multiple neurohormonal factors. The physiologic mechanisms of this condition continue to evolve, with an ever-widening array of hormones, cytokines, adipokines, and gut peptides implicated in its development. As our understanding of this condition widens, an exciting new array of current and future pharmacologic and interventional procedures will become available in the treatment of this increasingly common condition. Nonetheless, the fundamental concept of plasma volume expansion in the setting of impaired natriuresis and increased sympathetic tone continues to be the cornerstone in understanding obesity-hypertension.
Weight loss remains paramount in treatment of hypertension and the other metabolic consequences of obesity, and bariatric surgery continues to be the most effective proven method of sustained weight loss. Hypertension improves in most patients in response to this type of surgery, though results clearly favor surgical techniques involving bypass or resection of the stomach over restrictive procedures such as gastric banding, suggesting a prominent role in the gastrointestinal peptides in obesity-hypertension development and treatment. In general, a clinician can expect approximately 60-80% of patients will have some degree of improvement with bypass/resection type surgeries, and roughly half with have similar improvement with gastric banding.
However, though long-term improvement in hypertension after bariatric surgery appears more promising than previously reported, clinicians and patients should be cognizant of a lessened effect over time, perhaps secondary to age-related hypertension progression, and must remain diligent in clinical follow-up and lifestyle modification following these procedures. Furthermore, any decision to undergo bariatric surgery must also take into account the overall metabolic risk vs. the potential of a devastating complication of a major procedure.
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